- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
453
Companies which are more than 50% undervalued based on analyst price target.
453 companies
Calidi Biotherapeutics
Market Cap: US$6.2m
A clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
CLDI
US$1.52
7D
-5.0%
1Y
-88.4%
Mainz Biomed
Market Cap: US$6.0m
Develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.
MYNZ
US$1.49
7D
-9.1%
1Y
-85.6%
Oragenics
Market Cap: US$5.5m
A development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
OGEN
US$1.31
7D
-3.0%
1Y
-88.9%
CNS Pharmaceuticals
Market Cap: US$5.1m
A clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
CNSP
US$9.00
7D
9.8%
1Y
-88.4%
GRI Bio
Market Cap: US$5.0m
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
GRI
US$2.06
7D
5.6%
1Y
-63.8%
Soligenix
Market Cap: US$4.8m
A late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
SNGX
US$1.16
7D
-40.5%
1Y
-69.5%
Aptevo Therapeutics
Market Cap: US$4.7m
A clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
APVO
US$1.45
7D
-11.6%
1Y
-98.8%
Jaguar Health
Market Cap: US$4.6m
A commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
JAGX
US$2.33
7D
15.9%
1Y
-92.4%
Bone Biologics
Market Cap: US$4.3m
A medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
BBLG
US$2.79
7D
31.0%
1Y
-77.6%
Biodexa Pharmaceuticals
Market Cap: US$4.1m
A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.
BDRX
US$6.65
7D
5.6%
1Y
-91.3%
Quoin Pharmaceuticals
Market Cap: US$4.1m
A late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
QNRX
US$7.19
7D
0.3%
1Y
-57.3%
Theriva Biologics
Market Cap: US$3.8m
A clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
TOVX
US$0.41
7D
1.7%
1Y
-68.4%
Dermata Therapeutics
Market Cap: US$3.5m
A late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications.
DRMA
US$5.02
7D
-3.5%
1Y
-67.2%
Revelation Biosciences
Market Cap: US$3.3m
Operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.
REVB
US$1.42
7D
-3.4%
1Y
-96.5%
Indaptus Therapeutics
Market Cap: US$3.3m
A clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
INDP
US$2.87
7D
-7.7%
1Y
-91.3%
Azitra
Market Cap: US$2.5m
An early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.
AZTR
US$0.70
7D
-4.4%
1Y
-79.8%
Windtree Therapeutics
Market Cap: US$2.3m
A biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
WINT
US$0.067
7D
-15.9%
1Y
-99.9%
GT Biopharma
Market Cap: US$2.1m
A clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms.
GTBP
US$0.59
7D
-28.9%
1Y
-73.6%
Silexion Therapeutics
Market Cap: US$1.9m
A biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
SLXN
US$3.40
7D
-5.6%
1Y
-95.5%
Unity Biotechnology
Market Cap: US$963.0k
A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
UNBX
US$0.056
7D
-20.0%
1Y
-96.1%
Medicine Man Technologies
Market Cap: US$8.6k
Medicine Man Technologies, Inc., doing business as Schwazze, engages in the cultivation, manufacturing, distribution, and retail sale of cannabis and cannabis related products in Colorado and New Mexico.
SHWZ
US$0.0001
7D
-90.0%
1Y
-99.9%